{"id":39237,"date":"2021-06-30T12:00:44","date_gmt":"2021-06-30T12:00:44","guid":{"rendered":"https:\/\/biomedpharmajournal.org\/?p=39237"},"modified":"2021-07-23T11:58:55","modified_gmt":"2021-07-23T11:58:55","slug":"the-effect-of-miana-coleus-scutellariodes-l-on-vascular-endothelial-growth-factor-expression-in-balbc-mice-infected-with-mycobacterium-tuberculosis","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol14no2\/the-effect-of-miana-coleus-scutellariodes-l-on-vascular-endothelial-growth-factor-expression-in-balbc-mice-infected-with-mycobacterium-tuberculosis\/","title":{"rendered":"The Effect of Miana (Coleus Scutellariodes [L]) on Vascular Endothelial Growth Factor Expression in Balb\/C Mice Infected with Mycobacterium Tuberculosis"},"content":{"rendered":"

Introduction<\/strong><\/p>\n

Tuberculosis (TB) is one of the major health problem in the world.\u00a0 It ranks tenth as the cause of death in the world. World Health Organization (WHO)<\/em>reported 10 million cases of TB cases and 1.3 million deaths globally in 2018. It is estimated that two thirds of TB burden lies in eight countries which are India (27%), China (9%), Indonesia (8%), Philipphines (6%), Pakistan (5%), Nigeria (4%), Bangladesh (4%) dan South Africa (3%). WHO 2018 report estimated there were more than 1 million new TB cases in indonesia.1,2,3<\/sup><\/p>\n

The problem in battling TB is the increasing antibiotic resistant TB cases in indonesia.Indonesia is ranked 8th<\/sup> out of 27 countries with the highest cases of multi drug resistant (MDR) TB in the world.4,5,6<\/sup>This showed that there is a need for additional means to treat TB in addition to the administration of antibiotic. While antibiotic work to eradicate pathogen bacteria, it is important to increase host immune responseto M. tuberculosis<\/em> bacterial virulence to create a synergy between antibiotics and immunoregulators.7,8<\/sup><\/p>\n

When M. tuberculosis<\/em> invade the host cell, inflammation occurs as the host immune response. This inflamatory response creates local hipoxia due to increased metabolic activity and thus creating increased temperature in the inflamed tissue. The rise in local tissue temperature affect the amount and pressure of local oxygen and creates cellular hypoxia and inflammation.9,10<\/sup>Low oxygen level and inflammatory citokines IL-1\u03b1 and IL-6 induces the\u00a0expression of VEGF mRNA.11,12<\/sup>Vascular endothelial growth factor (VEGF) plays a role in angiogenesis and angiogenesis increases blood flow to ichemic cells and tissues and corrects hypoxia.13,14<\/sup><\/p>\n

The use of traditional herbal medicine widely in infectious diseases 15,16,17,18,19,20,21,22,23<\/sup>and non infectious diseases such as has been a staple alternative to western medicine for indonesian people. 24,25,26,27,28<\/sup>Recently, traditional herbal medicine may become an alternative or adjuvant to standard therapy.Miana (Coleus scutellariodes [L] Benth) <\/em>is known as one of the traditional herbal medicine that is often used. It contains flavonoid, tanin, triterpenoid, steroid and atsiri oil that has antibacterial, antioxidant and antiinflammatory effects.29,30,31,32<\/sup><\/p>\n

Miana leaves haveendophyte bacteria that have the ability to synthesize antibacterial agent that contains phtalic acid derivate.In one in vitro study, Miana extract can suppress the growth of Candida albicans and Salmonella typhi<\/em>.33,34,35<\/sup>A study found that Miana extract can improve host immunity by modifying the degree and quality of immune response from T cell, B cell, IL-10 and IL-37.Miana extract can affect proliferation of T cells in mice that was given 510mg\/kgBW of Miana extract.Administration of Miana extract also increases the number of CD4 T cells, IFN-\u03b3 levels, IL37and TNF-\u03b1 and also reduces the bacterial colonies in Wistar mice\u2019s lungs.31,32,36,37<\/sup><\/p>\n

Other that immunostimulant and immunoregulatory effects, Miana also has antiinflammatory and antioxidant properties.In Salmonella typhi<\/em>infected Balb\/c mice model, Miana leaves extract can suppress the expression oftoll like receptor-4 <\/em>(TLR-4) m-RNA which is similar to the effect produced by antibiotics.32<\/sup><\/p>\n

However, not much is known about theeffect of Miana leaves extract on VEGF, one of the pivotal factor on combating cell hypoxia due to M. tuberculosis<\/em> infection.This study aims to elucidate the effect of Miana on VEGF expression in Balb\/c mice infected with M. tuberculosis.<\/p>\n

Material and methods<\/strong><\/p>\n

Experimental Design<\/strong><\/p>\n

This study is an experimental study using 16 BALB\/c miceconducted in July 2020 in Molecular Biology and Immunology Laboratory, Microbiology Division, Faculty of Medicine, Hasanuddin University (UNHAS), Makassar, Indonesia. The micewere grouped into four groups of four mice. Group 1 is a negative control group that was treated with placebo. Group 2 is a\u00a0positive control group that was treated with antituberculosis drug. Group 3 is an intervention group that was treated with Miana extract. Group 4 is also an intervention group that was treated with Miana extract and antituberculosis drug.<\/p>\n

Balb\/c Mice<\/strong><\/p>\n

Sixteen 12 weeks old pathogen free BALB\/c mice weighing 30-40 grams were uses in this experiment. The mice were granted by UNHAS Molecular Biology and Immunology Laboratory, Faculty of Medicine, Makassar, Indonesia.<\/p>\n

Miana Extract<\/strong><\/p>\n

Miana leaves were obtained from Toraja, Middle Sulawesi, Indonesia. The Miana extract was made using 10 grams of plucked Miana Leaves that were washed and dried in 50 C oven. The dried leaves were grinded using a grinder and sieved using size 100 mesh to achieve fine powder from. A total of 30 grams of Miana powder was diluted with ethanol with 1:10 ratio and mixed using a shaker for 24 hours in room temperature. The mixture was filtered using Whatman\u00a0filter paper number 50. The filtrate was evaporated using a rotary evaporator in 50 C temperature until concentrated and then dried using a freeze dryer. The concentrated extract was made into a pellet.<\/p>\n

The pellets were stored in a refrigerator until use. The dosage of Miana extract used in this experiment was 510 mg\/kgBW. The pellets will be diluted with aquades and given to the mice using a nasogastric tube.32,33<\/sup><\/p>\n

Tuberculosis Induction<\/strong><\/p>\n

tuberculosis induction was done by injecting 103<\/sup> CFU\/ml of M. tuberculosis into the peritoneal cavity using a 0.6 ml syringe.16,17,18<\/sup><\/p>\n

Miana treatment in mice <\/strong><\/p>\n

All 16 Balb\/c mice were put into groups of 4 (group 1-4) randomly. On day 0, 0.2 ml of venous blood was drawn (before induction and before treatment blood sample) from all mice in all groups and M. tuberculosis<\/em> induction was done on all mice. On day 1, the second blood draw\u00a0(after induction before treatment blood sample) was done on all groups. Group 1 was given 10 mg\/kgBW\/day of aquadest as placebo, group 2 was given 1.95 mg\/day of rifampicin, group 3 was given 750 mg\/kgBW of Miana extract, group 4 was given 1.95 mg\/day of rifampicin and\u00a0750 mg\/kgBW of Miana extract. From day 1 to day 7, the treatment specific to each group was continued. On day 8, the third blood draw (after treatment blood sample) was done.<\/p>\n

Venous blood sample was centrifugated to obtain the blood serum. The serum was stored in -20 C until analysis. VEGF protein level was measured using Mouse VEGF Elisa Kit Catalog No. LS-F978. Protein concentration was measured in pg\/ml. VEGF protein level before induction, before treatment, and after treatment of all groups were done. All sample analysis was done in duplicate to ensure validity of ELISA analysis results.<\/p>\n

Statistical Analysis<\/strong><\/p>\n

Normality test was done using Shapiro-Wilk test and Levene\u2019s test was done for homogeneity test. Protein levels of each groups were presented in means and standard deviation. One way ANOVA test was used to determine whether there are any statistically significant differences between the means of VEGF protein levels of the treatment groups as a whole.Post hoc test was done to determine which group is statistically significantly different from other groups. P value below 0.05 is determined as statistically significant. All statistical analyses were done using SPSS 20.0 software for Windows.<\/p>\n

Results and Discussion<\/strong><\/p>\n

VEGF protein levels before induction, after induction, and after treatment<\/strong><\/p>\n

Table 1 showed the means of VEGF protein level before M. Tuberculosis infection, after infection, and after treatment of all four treatment groups. The mean \u00b1 SD of VEGF in group 1 (placebo) was 3,631.360 \u00b1 2,261.273 pg\/ml before infection, 17,575.417 \u00b1 2,041.037 pg\/ml after infection, and 21,595.533 \u00b1 2,442.347 pg\/ml after treatment. In group 2 (rifampicin), the mean \u00b1 SD of VEGF was 2,393.661 \u00b1 1,747.450pg\/ml before infection, 18,083.191 \u00b1 1,876.923pg\/ml\u00a0after infection, and 4,655.215 \u00b1 1,731.676pg\/ml after treatment. In group 3 (Miana), the mean \u00b1 SD of VEGF was 3,901.364 \u00b1 2,234.894 pg\/ml before infection, 17,125.172 \u00b1 1,738.783 pg\/ml after infection, and 7,419.336 \u00b1 1,765.879pg\/ml after treatment. Lastly, the mean \u00b1 SD of VEGF in group 4 (Miana and Rifampicin) was 2,128.043 \u00b1 865.085 pg\/ml before infection, 17,195.564 \u00b1 1,856.413 pg\/ml after infection, and 3,837.384 \u00b1 957.187 pg\/ml after treatment.<\/p>\n

Table 1: VEGF Protein Levels of All Groups<\/strong><\/p>\n\n\n\n\n\n\n\n
Group<\/strong><\/td>\nBefore infection<\/strong><\/td>\nAfter Mtb Infection<\/strong><\/td>\nAfter Treatment<\/strong><\/td>\n<\/tr>\n
Group2 (Rifampicin)<\/td>\n2393.661 \u00b1 1747.450<\/td>\n18083.191 \u00b1 1876.923<\/td>\n4655.215 \u00b1 1731.676<\/td>\n<\/tr>\n
Group3 (Miana)<\/td>\n3901.364 \u00b1 2234.894<\/td>\n17125.172 \u00b1 1738.783<\/td>\n7419.336 \u00b1 1765.879<\/td>\n<\/tr>\n
Group4(Rif + Miana)<\/td>\n2128.043 \u00b1 865.085<\/td>\n17195.564 \u00b1 1856.413<\/td>\n3837.384 \u00b1 957.187<\/td>\n<\/tr>\n
Group 1 (Placebo)<\/td>\n3631.360 \u00b1 2261.273<\/td>\n17575.417 \u00b1 2041.037<\/td>\n21595.533 \u00b1 2442.347<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

*Mtb = M. tuberculosis<\/em><\/p>\n

Table 2: One Way ANOVA Differences of Means Between Groups<\/strong><\/p>\n\n\n\n\n\n\n\n
Group<\/strong><\/td>\nAfter Treatment<\/strong><\/td>\nF <\/strong><\/td>\nNilai P<\/strong><\/td>\n<\/tr>\n
Group 2 (Rifampicin)<\/td>\n4655.215<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Group 3 (Miana)<\/td>\n7419.336<\/td>\n105.710<\/td>\n0.000<\/td>\n<\/tr>\n
Group 4 (Rif + Miana)<\/td>\n3837.384<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Group 1 (Placebo)<\/td>\n21595.533<\/td>\n<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

From the description of the obtained data, it can be seen that there is a steep increase of VEGF protein levels after M. Tuberculosis infection. The level of VEGF protein kept increasing after placebo treatment in group 1 while the VEGF levels in other groups decreased after treatment. One-Way ANOVA test was done to see whether there is a significant difference of means after treatment in general. The test result showed a significant difference of VEGF protein\u00a0level means between groups after treatment in general (Table 2; F = 105.710, p value = 0.000). To further analysethe difference of VEGF protein level means between groups, a post hoc analysis was done.<\/p>\n

Post hoc analysis (Table 3) showed that VEGF protein level was significantly lower after administration of rifampicin (4,655.215 \u00b1 1,731.676 pg\/ml, p value = 0.000), Miana (7,419.336 \u00b1 1,765.879 pg\/ml, p value = 0.000), and rifampicin plus Miana (3,837.384 \u00b1 957.187 pg\/ml, p value = 0.000) compared to placebo (21,595.533 \u00b1 2,442.347 pg\/ml).VEGF protein level was\u00a0significantly lower in mice treated with rifampicin (4,655.215 \u00b1 1,731.676 pg\/ml, p value = 0.028)compared to the mice treated withMiana (7,419.336 \u00b1 1,765.879 pg\/ml) and no significant difference between rifampicin group and rifampicin plus Miana group (p value = 0.484). There\u00a0was also a significantly lower VEGF protein level in mice treated with rifampicin plus Miana (3,837.384 \u00b1 957.187 pg\/ml, p value = 0.006) compared to mice treated with Miana (7,419.336 \u00b1 1,765.879 pg\/ml).<\/p>\n

Table 3: Post Hoc Analysis of Mean Differences<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Group<\/strong><\/td>\nSubgroup<\/strong><\/td>\nMean differences<\/strong><\/td>\nNilai P<\/strong><\/td>\n<\/tr>\n
Rifampicin<\/td>\nMiana<\/td>\n-2764.12160*<\/sup><\/td>\n.028<\/td>\n<\/tr>\n
<\/td>\nRif + Miana<\/td>\n817.83080<\/td>\n.484<\/td>\n<\/tr>\n
<\/td>\nPlacebo<\/td>\n-16940.31780*<\/sup><\/td>\n.000<\/td>\n<\/tr>\n
Miana<\/td>\nRif<\/td>\n2764.12160*<\/sup><\/td>\n.028<\/td>\n<\/tr>\n
<\/td>\nRif + Miana<\/td>\n3581.95240*<\/sup><\/td>\n.006<\/td>\n<\/tr>\n
<\/td>\nPlacebo<\/td>\n-14176.19620*<\/sup><\/td>\n.000<\/td>\n<\/tr>\n
Rifampicin + Miana<\/td>\nRif<\/td>\n-817.83080<\/td>\n.484<\/td>\n<\/tr>\n
<\/td>\nMiana<\/td>\n-3581.95240*<\/sup><\/td>\n.006<\/td>\n<\/tr>\n
<\/td>\nPlacebo<\/td>\n-17758.14860*<\/sup><\/td>\n.000<\/td>\n<\/tr>\n
Placebo<\/td>\nRif<\/td>\n16940.31780*<\/sup><\/td>\n.000<\/td>\n<\/tr>\n
<\/td>\nMiana<\/td>\n14176.19620*<\/sup><\/td>\n.000<\/td>\n<\/tr>\n
<\/td>\nRif + Miana<\/td>\n17758.14860*<\/sup><\/td>\n.000<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Discussion <\/strong><\/p>\n

Tuberculosis is infectious diseases which their pathomechanisms has been involve the several immune system both cellular and humoral system.38,39<\/sup>Serum VEGF levels is known to be elevated in patients with active pulmonary tuberculosis and lowered after successful treatment.40<\/sup>In this study, VEGF levels were also elevated after the mice was infected with M.\u00a0tuberculosis and decreased after treatment whereas VEGF level in placebo treated mice kept increasing. This indicates the role of VEGF in Tuberculosis infection.<\/p>\n

This study found that there was a significant difference in VEGF level means between groups in general. Further investigation showed that VEGF levels were significantly lower in M. Tuberculosis-infected mice treated with rifampicin, Miana, and rifampicin plus Miana compared to placebo. VEGF level was also lower in rifampicin group compared to Miana group. There was also a significantly lower VEGF level in rifampicin plus Mianagroup compared to Miana group. However, there was no significant difference of VEGF level between rifampicin group and rifampicin plus Miana group.This result indicate that Miana extract administration does have an effect on VEGF protein levels. Our result showed that rifampicin with Miana extract as adjuvant can be an acceptable Tuberculosis treatment.<\/p>\n

However, the exact mechanism of how Miana extract affect VEGF in Tuberculosis infection remains unclear. To elucidate the possible mechanism of the effect of Miana extract on VEGF production, understanding of tuberculosis infection immune response pathway and the mechanism of Miana extract as antimicrobial, anti-inflammatory, and antioxidant are crucial.<\/p>\n

During infection such as tuberculosis infection, inflamed site due to infection is relatively hypoxic. Hypoxic environment increases the cellular level of HIF-1\u03b1. The increase in HIF-1\u03b1 will increase the level of VEGF. There are multiple other pathways of VEGF production induction in during infection.40<\/sup>Inflammation caused by infection stimulates the production of\u00a0cyclooxygenase (COX) 1 and COX 2 which will induce the production of prostaglandin E2 (PGE2). PGE2 and HIF-1\u03b1 upregulates the production of cellular VEGF. Upregulation of cellular VEGF enhances angiogenesis, vasodilatation, mediate extravasation of monocytes under hypoxic condition, and works together with histamine to increase vascular permeability which causes plasma exudation.41<\/sup><\/p>\n

Miana is one of the traditional herbal medicine commonly used to treat infectious diseases and immune booster by the Toraja people in South Sulawesi, Indonesia. It is also commonly used as a complement to antituberculosis treatment. To be used, Miana leaves needs to be extracted. Miana leaves extract contains compounds such as alkaloids, tannins, flavonoids, saponins and terpenoids. Flavonoids have antimicrobial, antiinflammatory and antioxidant<\/p>\n

properties. One study stated that flavonoid content in miana extract is on average 8.59 mg\/gram extract. Flavonoid antibacterial mechanism consists of inhibition of nucleic acid synthesis and causing damage to bacterial cell wall, microsomes, and lysosomes. Flavonoids also has very strong antioxidant activity. Flavonoid in Mianaincreases T lymphocytes, CD4 T cells, IFN-y, IL-37, TNF- \u03b1, TLR4and NRAMP1. Tannin, saponin, and terpenoid also have antimicrobial activity.31,32,33,36<\/sup><\/p>\n

From the explanation above, it is clear that M. tuberculosis<\/em> infection causes inflammation and hypoxia and activates a cascade of immune response in which at one of the ends of the line increases VEGF protein levels to combat the bacteria as well as hypoxia. Miana extract, which contains flavonoids and others, directly acts on the bacteria as a type of antibacterial as well as immunoregulator to increase host immune response to combat the bacteria and anti-inflammatory action. The elimination or reduction of the cause of the inflammation diminishes the signal for the induction of upregulation of VEGF. This may explain the possible mechanism of the effect of Miana on VEGF levels. Further study is needed to elucidate the immunoregulatory pharmacodynamics of Miana leaves extract.<\/p>\n

Conclusion<\/strong><\/p>\n

There were significant differences in VEGF protein levels between treatment groups. VEGF protein levels in Balb\/c mice treated with rifampicin, Miana, and rifampicin plus Miana were significantly lower than placebo. VEGF protein levels were significantly lower in rifampicin treatment group compared to Miana group; significant lower VEGF protein level in\u00a0rifampicin plus Miana treatment group compared to Miana group; and no significant difference between rifampicin group and rifampicin plus Miana group.<\/p>\n

Acknowledgement<\/strong><\/p>\n

The author would like to thank the Molecular Biology and Immunology Laboratory staffs and consultants for their continuous help and support for the completion of this study.<\/p>\n

Conflict of interest<\/strong><\/p>\n

There are no potential conflict of interest to be disclosed.<\/p>\n

Funding source<\/strong><\/p>\n

The study was funded privately by authors. There were no sponsorsinvolvement in the study.<\/p>\n

References<\/strong><\/p>\n

    \n
  1. World Health Organization. Global Tuberculosis Report 2020. Geneva: World Health Organization<\/em>. 2020.<\/li>\n
  2. ScheelbeekPFD, Wirix AJG, Hatta M, Usman R, Bakker MI. Risk factors for poor tuberculosis treatment outcomes in Makassar, Indonesia. Southeast Asian J Trop Med Public Health<\/em>. 45 (4):853-858 (2014).<\/li>\n
  3. Hatta M, Sultan AR, Tandirogang N, MasjudiM,Yadi Y. Detection and identification of mycobacterium in sputum from suspected tuberculosis patients. BMC Research Notes<\/em>, 3: 72 (2010).doi: 10.1186\/1756-0500-3-72.
    \nCrossRef<\/a><\/li>\n
  4. Suryanto AA, van den Broek J, Hatta M, de Soldenhoff R, van der Werf MJ. Recurrence of tuberculosis in patients treated with single-dose drugs in Combi-packs and fixed-dose combination (4FDC) drugs in South Sulawesi, Indonesia. Int J Tub Lung Dis<\/em>.12(2) :174-179 (2008).<\/li>\n
  5. Umar F, Hatta M, Husain DR, Dwiyanti R, Natzir R, Sjahril S, Junita AR, Primaguna MR. Molecular characterization of mutation associated with resistances to first- and second-line tuberculosis drug among tuberculosis patients in Makassar, Indonesia. J Taibah Univ Med Sci<\/em>. 15(1):54-58. (2020). https:\/\/doi.org\/10.1016\/j.jtumed.2019.12.003.
    \n    CrossRef<\/a><\/li>\n
  6. UmarF, Hatta M, Husain DR, Bahar B, Bukhari A, Dwiyanti R, Junita AR, Primaguna MR. Verapamil as an Efflux Inhibitor Against Drug Resistant Mycobacterium Tuberculosis: A Review. Sys Rev Pharm<\/em>. 10(1) Suppl: s43-s48. (2019). DOI:10.5530\/srp.2019.1s.22.<\/li>\n
  7. Umar F, Hatta M, Husain DR, Natzir R, Dwiyanti R, Junita AR, Primaguna MR. The effect of anti-tuberculosis drugs therapy towards mRNA efflux pump gene expression of Rv1250 in Mycobacterium tuberculosis collected from tuberculosis patients. New Microb New Infect<\/em>. 32(C):1-7 (2019) https:\/\/doi.org\/10.1016\/j.nmni.2019.100609.
    \n    CrossRef<\/a><\/li>\n
  8. Hatta M, Ratnawati, Tanaka M, ItoJ, Shirakawa T, Kawabata M. NRAMP1\/SLC11A1 gene polymorphisms and host susceptibility to Mycobacterium tuberculosis and leprae in South Sulawesi, Indonesia. Southeast Asian J. Trop Med Public Health<\/em>. 41(2): 386-394 (2010).<\/li>\n
  9. Ramakrishnan S, Anand V, Roy S. Vascular Endothelial Growth Factor Signaling in Hypoxia and Inflammation. J Neuroimmune Pharm<\/em>. 9(2):142-60 (2014).
    \n    CrossRef<\/a><\/li>\n
  10. Purnamanita, Budu, Hatta M, Massi MN, Natzir R, IchsanA. Sujuti H. The Effectiveness of Triamcinolone Injection on Risk of Postoperative Operations with the Conjunctiva Autograft Technique and Its Association with Change of VEGF mRNA Expression. Biomed Pharmacol J.<\/em>13(2):543-549. (2020). http:\/\/dx.doi.org\/10.13005\/bpj\/1916
    \n    CrossRef<\/a><\/li>\n
  11. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J<\/em>. 13:9-22 (1999).
    \n    CrossRef<\/a><\/li>\n
  12. Oley MH, Oley MC, Noersasongko AD, Hatta H, PhilipsGG, Agustine, Faruk M, Kalangi JA, Irene MA. Rumampuk, Tulong MT. Effects of hyperbaric oxygen therapy on vascular endothelial growth factor protein and mRNA in crush injury patients: A randomized controlled trial study.Int J Surgery Open<\/em>. 29(2021): 33-39 (2021). https:\/\/doi.org\/10.1016\/j.ijso.2021.01.003.
    \n    CrossRef<\/a><\/li>\n
  13. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel A, Nizet V, Johnson R, Haddad G, Karin M. NF-\u03baB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1\u03b1. Nature<\/em>. 453(7196):807-11 (2008).
    \n    CrossRef<\/a><\/li>\n
  14. OleyMH, Oley MC, Tjandra DE, Sedu SW, SumarauwERN, Aling DMR, Hatta M, Faruk M. Hyperbaric oxygen therapy in the healing process of foot ulcers in diabetic type 2 patients marked by interleukin 6, vascular endothelial growth factor, and PEDIS score: A randomized controlled trial study. Int J Surgery Open<\/em>. 27 (2020):154-161. (2020). https:\/\/doi.org\/10.1016\/j.ijso.2020.11.012 (2020).
    \n    CrossRef<\/a><\/li>\n
  15. Kamelia E, Islam AA, Hatta M, Miko H, Karo M. Evaluation of the Activity of F2-isoprostane in Alzheimer\u2019s Disease Rats Given Banana Extract. Pakistan J Med Health Sci<\/em>. 14(2):1459-1564 (2020)<\/li>\n
  16. Febriza A, Natzir R, Hatta, Uiterwaal CSPM, As’ad S, Budu B, Alam G, Kasim VN,Idrus HH. Curcumin Effects in Inducing mRNA Gene Cathelidicin Antimicrobial Peptide (CAMP) in Balb\/c Mice Infected with Salmonella Typhi. J Biol Res – BollettinodellaSociet\u00e0Italiana di BiologiaSperimentale<\/em>. 93(2):76-80 (2020). https:\/\/doi.org\/10.4081\/jbr.0.8942
    \n    CrossRef<\/a><\/li>\n
  17. Kasim VN, Hatta M, Natzir M, Hadju V, Hala Y, Budu, Alam G, As’ad S,Febriza A,Idrus HH. Antibacterial and anti-inflammatory effects of lime (Citrus aurantifolia) peel extract in Balb\/c mice infected by Salmonella typhi. J Biol Res – BollettinodellaSociet\u00e0Italiana di BiologiaSperimentale<\/em>. 93(2):81-84 (2020). DOI: 10.4081\/jbr.0.8951.
    \n    CrossRef<\/a><\/li>\n
  18. Idrus HH, Hatta M, Febriza A, Kasim VN. Antibacterial activities of Sapodilla fruit extract inhibiting Salmonella typhi in mice Balb\/c. Int J Applied Pharmaceutics<\/em>.11(5):121-126 (2019). http:\/\/dx.doi.org\/10.22159\/ijap.2019.v11s5.T0095
    \n    CrossRef<\/a><\/li>\n
  19. Sirait LI, Massi MN, Hatta M, Prihantono. The Effects of Extract Andaliman Fruit (Zanthoxylum acanthopodium Dc) to CAMP mRNA expression and Bacterial Load in Mice Balb-C after Gardnerella vaginal Infection. Indian J Pub Health Res Dev<\/em>. 9(11): 607-611 (2019). DOI: 10.5958\/0976-5506.2018.01525.5
    \n    CrossRef<\/a><\/li>\n
  20. Tambaip T, Karo M, Hatta M, Dwiyanti R, Natzir R, Massi MN, Islam AA,Djawad K. Immunomodulatory effect of orally red fruit (Pandanus\u00a0 conoideus) extract on the expression of CC chemokine receptor 5 mRNA in HIV patients with antiretroviral therapy. Res J Immunol<\/em>.11:15-21.(2018). DOI: 10.3923\/rji.2018.15.21.
    \n    CrossRef<\/a><\/li>\n
  21. Simanjuntak TP, Hatta M, Rauf S, Prabandari SA, Siagian, Dwiyanti R. Tumor Necrosis Factor-alpha Levels and Histopathology Finding after Intervention with Curcuma longa Extract. J Med Sci<\/em>.18 (2): 56-62 (2018). DOI: 10.3923\/jms.2018.56.62
    \n    CrossRef<\/a><\/li>\n
  22. Irawaty DA, Hasanuddin T, Hatta M, Harun A, Ainul W. Differences of Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) of Moringa Leaf Extract (Moringa Oliefera L.) on Bacteria Aggregatibacter Actinomycetemcomitans and PorphyromonasGingivalis. Indian J Pub Health Res Dev<\/em>.10(8): 896- 900(2019). DOI : 10.5958\/0976-5506.2019.02007.2.
    \n    CrossRef<\/a><\/li>\n
  23. Simanjuntak TP,Hatta M, Tahir AM, Sirait RH, Karo M, Tambaib T, Dwiyanti R,Noviyanthi RA, Junita AR. Analysis of Anti-toxoplasma Immunoglobulin G and Immunoglobulin M Antibody Levels after Intervention with Curcuma Longa Extract on Early Pregnant Mice with Acute Toxoplasmosis. J Global Infect Dis<\/em>.11:25-29 (2019).DOI: 10.4103\/jgid.jgid_28_18.
    \n    CrossRef<\/a><\/li>\n
  24. Aritonang R, Natzir R, Sinrang W, Massi MN, Hatta M, M.Kamelia E. The Effect of Administration of Extract from Areca Nut Seeds (Areca Catechu L) on the Estradiol and Estrus Cycle Balb\/C Female Rats. J Physics: Conference Series<\/em>. 1477 (6):1-6 (2020). doi:10.1088\/1742-6596\/1477\/6\/062026
    \n    CrossRef<\/a><\/li>\n
  25. Djais AI, Thahir H, Hatta M, Achmad H, Sari M. Effect of Moringa Leaf Extract (Moringa Oleifera) on Increasing the Number of Osteoblast as a Marker of Bone Remodeling. Indian J Pub Health Res Dev<\/em>. 10(9):1394-1398 (2019)
    \n    CrossRef<\/a><\/li>\n
  26. Rosyidi RM, Januarman, Priyanto B, Islam AA, Hatta M, Bukhari A. The Effect of Snakehead Fish (Channastriata) Extract Capsule to the Albumin Serum Level of Post-operative Neurosurgery Patients. Biomed Pharmacol J<\/em>.12(2): 893-899 (2019).http:\/\/dx.doi.org\/10.13005\/bpj\/1714.
    \n    CrossRef<\/a><\/li>\n
  27. Mulyawan E, Ahmad MR, Islam AA, Massi MN, Hatta M, Arif SK. Effect of Valerian Extract on GABRB3 Gene Expression and Sedation in BALB\/C Mice. Current Bioactive Compounds<\/em>.16(8):1249-1257 (2020). DOI: 10.2174\/1573407216999200620185627
    \n    CrossRef<\/a><\/li>\n
  28. Royani I, As\u2019ad S, Mappaware NA, Hatta M, Rabia. Effect of Ajwa Dates Consumption to Inhibit the Progression of Preeclampsia Threats on Mean Arterial Pressure and Roll-Over Test. BioMed Research J<\/em>. 2019, Article ID 2917895 (2019). https:\/\/doi.org\/10.1155\/2019\/2917895
    \n    CrossRef<\/a><\/li>\n
  29. Syarif LI, Junita AR, Hatta M, Dwiyanti R, Kaelan K, Sabir M, Primaguna MR, Purnamasari NI. A Mini Review: Medical Plants for Typhoid Fever in Indonesia. Systematic Reviews in Pharmacy<\/em>. 11(6):1171-1180. (2020). doi:10.31838\/srp.2020.6.170.<\/li>\n
  30. Syamsuri F, Hatta M, NatzirR, Alam G, Massi MN, Dwiyanti R, Bahar B. A Review: Worldwide Medicinal Plants for Typhoid Fever. Indian J Pub Health Res Dev<\/em>.9(8): 1461-1465. (2018). DOI:\u00a0 5958\/0976-5506.2018.00938.5
    \n    CrossRef<\/a><\/li>\n
  31. Yanto TA, Hatta M, Bukhari A, Natzir R. Molecular and Immunological Mechanism of Miana leaf (Coleus Scutellariodes<\/em> [L] Benth) in infectious diseases. Biomed Pharmacol J<\/em>. 13(4):1607-1618 (2020). https:\/\/dx.doi.org\/10.13005\/bpj\/2036.
    \n    CrossRef<\/a><\/li>\n
  32. Syamsuri F, Hatta M, Natzir R, Alam G, Massi MN, Bahar Bet al. Expression of TLR-4 in Salmonella typhi-Induced Balb\/c Mice Treated by Miana Leaves (Coleus scutellaroides<\/em> [L] Benth. Indian J. Public Heal Res Dev<\/em>. 9(12): 1449\u20131454 (2018).
    \n    CrossRef<\/a><\/li>\n
  33. Karo M, Hatta M, Salma W, Patellongi I, Natzir R. Effects of Miana (Coleus scutellaroides<\/em> [L] Benth) to expression of mRNA IL-37 in Balb\/C mice infected Candida albicans. Pharmacognosy J<\/em>.10(1):16-19 (2018).DOI : 10.5530\/pj.2018.1.3
    \n    CrossRef<\/a><\/li>\n
  34. Karo M, Tambaip T, Hatta M, Simanjuntak T, Irmawaty L, Rina T,KameliaE, Rahmawati, Bintang M. A mini Review of Indonesian Medical Plants for vulvovaginal candidiasis. Rasayan J. Chem<\/em>. 10(4:1280-1288 (2017). http:\/\/dx.doi.org\/10.7324\/ RJC.2017.1041887<\/li>\n
  35. Karo M, Hatta M, Patellongi I, Natzir R, Tambaip T. IgM antibody and colony fungal load impacts of orally administered ethanol extract of Plectranthusscutellarioides on mice with systemic candidiasis [Impacto de la administraci\u00f3n oral del extractoetan\u00f3lico de Plectranthusscutellarioidessobreanticuerpos IgM y la cargaf\u00fangicaenratones con candidiasis sist\u00e9mica]. Journal of Pharmacy & Pharmacognosy Research<\/em>.6 (1):27-34, (2018).http:\/\/jppres.com\/jppres<\/li>\n
  36. Wahyuni TD, Hatta M, Bukhari A, Santoso A, Massi MN, Increasing Natural Resistance Associated Macrophage Protein 1 serum level after Miana treatment in BALB\/c induced Klebsiella pneumoniae experimental research, Ann Med Surg<\/em>.65 (2021):102262. doi: https:\/\/doi.org\/10.1016\/j.amsu. 2021.102262.
    \n    CrossRef<\/a><\/li>\n
  37. Amsyah UK, Hatta M, Tahir H, Alam G, Asmawati A. Expression of IL-10 in A.actinomycetemcomitans Induced Rat Treated by Purple Miana Leaves. Biomedical and Pharmacology J<\/em>.12(4): 2099-2104. doi : http:\/\/dx.doi.org\/10.13005\/bpj\/1845.
    \n    CrossRef<\/a><\/li>\n
  38. Farsida, Hatta M, Patellongi I, Prihantono, Shabariyah R, Larasati RA, Islam AA, Natzir R,Nasrum M, Hamid F, DwiBahagia A, The Correlation of Foxp3+ Gene and Regulatory T Cells with Scar BCG Formation among Children with Tuberculosis.J Clin Tub Other Mycobact Dis<\/em>. 21 (2020)100202:1-7 (2020). https:\/\/doi.org\/10.1016\/j.jctube.2020.100202.
    \n    CrossRef<\/a><\/li>\n
  39. Farsida, Shabariah R, Hatta M, PatellongiI, Prihantono, Massi MN, Islam AA, Natzir R, DwiBahagiaA, Hamid F, Fatimah, Akaputra R, Savitri PA. Relationship between expression mRNA gene Treg, Treg, CD4+, and CD8+ protein levels with TST in tuberculosis children: A nested case-control.Ann Med Surgery<\/em>. 61: 44-47 https:\/\/doi.org\/10.1016\/j.amsu.2020.12.011. (2021)
    \n    CrossRef<\/a><\/li>\n
  40. Alatas F, Alatas O, Metintas M, Ozarslan A, Eerginal S, Yildirim H. Vascular endothelial growth factor levels in active pulmonary tuberculosis. Chest<\/em>.125(6):2156-2159 (2004).https:\/\/doi.org\/10.1378\/chest.125.6.2156.
    \n    CrossRef<\/a><\/li>\n
  41. Alkharsah KR. VEGF Upregulation in Viral Infections and Its Possible Therapeutic Implications. Int J Mol Sci<\/em>. 9(6):1642 (2018). doi: 10.3390\/ijms19061642.
    \n    CrossRef<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Introduction Tuberculosis (TB) is one of the major health problem […]<\/p>\n","protected":false},"author":14,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[92],"tags":[],"class_list":["post-39237","post","type-post","status-publish","format-standard","hentry","category-vol14no2"],"_links":{"self":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/39237","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/comments?post=39237"}],"version-history":[{"count":5,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/39237\/revisions"}],"predecessor-version":[{"id":39867,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/39237\/revisions\/39867"}],"wp:attachment":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/media?parent=39237"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/categories?post=39237"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/tags?post=39237"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}